Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Avastin Breast Cancer Study Proposal Not Enough To Save Current Claim, ODAC Concludes

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Oncologic Drugs Advisory Committee votes 6-0 for withdrawal of bevacizumab's accelerated approval for first-line metastatic breast cancer, despite Genentech's argument that the indication should be maintained while it conducts another confirmatory trial.
Advertisement

Related Content

Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval
Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech Appeals To FDA's "Regulatory Flexibility"
Genentech Appeals To FDA's "Regulatory Flexibility"

Topics

Advertisement
UsernamePublicRestriction

Register

PS072444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel